Randomized Multi-center Clinical Study:Bevacizumab for Neovascular Age-related Macular Degeneration
Randomized Multi-center Clinical Study:Bevacizumab for Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Inclusion Criteria:
Exclusion Criteria: